How Glenmark knocked Merck flat in a 3-D world
This article was originally published in Scrip
The recent dispute between Merck & Co and Glenmark over Glenmark’s sitagliptins (versions of Merck’s Januvia and Janument) shows that regulatory, administrative and legal variations around the globe can still befuddle multinational firms. Disentangling Merck’s learning journey through the controversial Section 3(d) of India's patent legislation illustrates how local factors make a difference.
You may also be interested in...
Circassia is returning the US rights to two COPD drugs to AstraZeneca as it admits it cannot meet its debt payments from the deal.
At their second meeting on COVID-19, drug regulators from around the world have stressed the importance of large, multi-arm studies in generating the data needed for the approval of potential coronavirus therapies. The European Medicines Agency, which organized the meeting, has also announced a new coronavirus task force to identify promising drug candidates and help steer them through development to regulatory approval.